Peer-reviewed veterinary case report
Oral feline interferon omega for immune support in FIV cats
By Gil, S et al.·Published in Research in veterinary science·2014·University of Lisbon (ULisboa)·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Oral Recombinant Feline Interferon-Omega as an alternative immune modulation therapy in FIV positive cats: clinical and laboratory evaluation.
- Species:
- cat
Plain-English summary
Eleven cats with Feline Immunodeficiency Virus (FIV) were treated with an oral immune-boosting medication called recombinant Feline Interferon-Omega for 90 days. Owners noticed significant clinical improvements in their cats' health, similar to those seen in cats treated with the standard injectable version of the medication. While the oral treatment did not significantly change viral levels or certain proteins in the blood, it still proved to be an effective alternative for managing FIV. This could be a good option for pet owners looking for different ways to support their FIV-positive cats.
People also search for: FIV treatment for cats · oral interferon for FIV cats · immune support for FIV-positive cats
Abstract
Recombinant-Feline Interferon-Omega (rFeIFN-ω) is an immune-modulator licensed for use subcutaneously in Feline Immunodeficiency virus (FIV) therapy. Despite oral protocols have been suggested, little is known about such use in FIV-infected cats. This study aimed to evaluate the clinical improvement, laboratory findings, concurrent viral excretion and acute phase proteins (APPs) in naturally FIV-infected cats under oral rFeIFN-ω therapy (0.1 MU/cat rFeIFN-ω PO, SID, 90 days). 11 FIV-positive cats were treated with oral rFeIFN-ω (PO Group). Results were compared to previous data from 7 FIV-positive cats treated with the subcutaneous licensed protocol (SC Group). Initial clinical scores were similar in both groups. Independently of the protocol, rFeIFN-ω induced a significant clinical improvement of treated cats. Concurrent viral excretion and APP's variation were not significant in the PO Group. Oral rFeIFN-ω can be an effective alternative therapy for FIV-infected cats, being also an option for treatment follow-up in cats submitted to the licensed protocol.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/24332273/